Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2022-03-08
Target enrollment:
Participant gender:
Summary
Background: Diabetes mellitus is commonly complicated by diabetic peripheral neuropathy. Due
to common side effects and poor tolerance to medication, poor adherence to medication is
common in diabetic peripheral neuropathy. Botulinum toxin A intradermal injection has proved
efficacy in cases of diabetic peripheral neuropathy however there is a need to compare its
effect with other lines of treatment. The aim of the study was to compare botulinum toxin
type a verses conventional oral treatment as a second line treatment of painful diabetic
peripheral neuropathy. we conducted a comparative study on 30 patients with type 2 diabetes
mellitus proved by nerve conduction study on carbamazepine. Patients were divided randomly
into 3 groups. First group was add on duloxetine, second was add on gabapentin and the third
group was injected intradermal with botulinum toxin A.
Phase:
Phase 4
Details
Lead Sponsor:
Alexandria University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A Duloxetine Hydrochloride Gabapentin